IFNG and neoplasm: To determine what cells were the key producers of IFN-γ, we tested CAR T-vax therapy employing IFN-γ-deficient CAR T-cells; this treatment elicited no antigen spreading (Figure 5I) and tumor control was lost, demonstrating an important role for CAR T-derived cytokine (Figure 5J).